Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Capricor Therapeutics (CAPR) PT Raised to $25 at Ladenburg Thalmann
May 14, 2024 6:46 AM EDTLadenburg Thalmann analyst Aydin Huseynov raised the price target on Capricor Therapeutics (NASDAQ: CAPR) to $25.00 (from $24.00) while maintaining a Buy rating.
The analyst comments "CAPR seems to have advanced in its regulatory negotiations with the FDA with possible rolling BLA... More
Capricor Therapeutics (CAPR) Misses Q1 EPS by 8c
May 13, 2024 4:11 PM EDTCapricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.91 million versus the consensus estimate of $7.05 million.
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
... More